Provider costs for prevention and treatment of cardiovascular and related conditions in low- and middle-income countries: a systematic review

BMC Public Health

Research Article

David Watkins¹  Rachel Nugent²  Elizabeth D. Brouwer²  Carol Levin²  Jane Goett³  Zachary Olson⁴ 

[1] Department of Medicine, University of Washington, Box 359780, 325 Ninth Ave, 98104, Seattle, WA, USA;Disease Control Priorities Network, Department of Global Health, University of Washington, Box 259931, 325 Ninth Avenue, 98104, Seattle, WA, USA;PATH, 2201 Westlake Ave #200, 98121, Seattle, WA, USA;School of Public Health, University of California Berkeley, #7360, 50 University Hall, 94720-7360, Berkeley, CA, USA;

关键词: Cardiovascular disease;    CVD;    Systematic review;    Economic evaluation;    Non-communicable disease;    Cost analysis;   

DOI  :  10.1186/s12889-015-2538-z

 received in 2015-01-07, accepted in 2015-11-23,  发布年份 2015

来源: Springer

【 摘 要 】

BackgroundThe burden of cardiovascular disease (CVD) and CVD risk conditions is rapidly increasing in low- and middle-income countries, where health systems are generally ill-equipped to manage chronic disease. Policy makers need an understanding of the magnitude and drivers of the costs of cardiovascular disease related conditions to make decisions on how to allocate limited health resources.MethodsWe undertook a systematic review of the published literature on provider-incurred costs of treatment for cardiovascular diseases and risk conditions in low- and middle-income countries. Total costs of treatment were inflated to 2012 US dollars for comparability across geographic settings and time periods.ResultsThis systematic review identified 60 articles and 143 unit costs for the following conditions: ischemic heart disease, non-ischemic heart diseases, stroke, heart failure, hypertension, diabetes, and chronic kidney disease. Cost data were most readily available in middle-income countries, especially China, India, Brazil, and South Africa. The most common conditions with cost studies were acute ischemic heart disease, type 2 diabetes mellitus, stroke, and hypertension.ConclusionsEmerging economies are currently providing a base of cost evidence for NCD treatment that may prove useful to policy-makers in low-income countries. Initial steps to publicly finance disease interventions should take account of costs. The gaps and limitations in the current literature include a lack of standardized reporting as well as sparse evidence from low-income countries.

【 授权许可】

CC BY   
© Brouwer et al. 2015